Patrick Fernandes Rodrigues

Patrick Fernandes Rodrigues

Auto-generated profile, based on publicly available information

Patrick Fernandes Rodrigues

Department of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2018 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
PRPatrick Fernandes Rodrigues
Patrick Fernandes Rodrigues
LALlucia Alberti-Servera
Llucia Alberti-Servera
AEAnna Eremin
Anna Eremin
GGGary E. Grajales-Reyes
Gary E. Grajales-Reyes
RIRobert Ivanek
Robert Ivanek
RTRoxane Tussiwand
Roxane Tussiwand

3 February 2023 in Science Immunology
Verified
Journal Article
Closed access
PRPatrick Fernandes Rodrigues
Patrick Fernandes Rodrigues
AKAthanasios Kouklas
Athanasios Kouklas
GCGrozdan Cvijetic
Grozdan Cvijetic
NBNicolas Bouladoux
Nicolas Bouladoux
MMMladen Mitrovic
Mladen Mitrovic
RTRoxane Tussiwand
Roxane Tussiwand
Plasmacytoid dendritic cells (pDCs) have been shown to play an important role during immune responses, ranging from initial viral control through the production of type I interferons to antigen presentation. However, recent studies uncovered unexpected heterogeneity among pDCs. We identified a previously uncharacterized immune subset, referred to as pDC-like cells, that not only resembles pDCs but also shares conventional DC (cDC) features. We show that this subset is a circulating precursor distinct from common DC progenitors, with prominent cDC2 potential. Our findings from human CD2-iCre and CD300c-iCre lineage tracing mouse models suggest that a substantial fraction of cDC2s originates from pDC-like cells, which can therefore be referred to as pre-DC2. This precursor subset responds to homeostatic cytokines, such as macrophage colony stimulating factor, by expanding and differentiating into cDC2 that efficiently prime T helper 17 (T H 17) cells. Development of pre-DC2 into CX3CR1 + ESAM − cDC2b but not CX3CR1 − ESAM + cDC2a requires the transcription factor KLF4. Last, we show that, under homeostatic conditions, this developmental pathway regulates the immune threshold at barrier sites by controlling the pool of T H 17 cells within skin-draining lymph nodes.

17 May 2024 in Science Immunology
Verified
Journal Article
Closed access
BLBlanda Di Luccia
Blanda Di Luccia
MMMartina Molgora
Martina Molgora
DKDarya Khantakova
Darya Khantakova
NJNatalia Jaeger
Natalia Jaeger
HCHao-Wei Chang
Hao-Wei Chang
MCMarco Colonna
Marco Colonna
The gut microbiota and tumor-associated macrophages (TAMs) affect tumor responses to anti–programmed cell death protein 1 (PD-1) immune checkpoint blockade. Reprogramming TAM by either blocking or deleting the macrophage receptor triggering receptor on myeloid cells 2 (TREM2) attenuates tumor growth, and lack of functional TREM2 enhances tumor elimination by anti–PD-1. Here, we found that anti–PD-1 treatment combined with TREM2 deficiency in mice induces proinflammatory programs in intestinal macrophages and a concomitant expansion of Ruminococcus gnavus in the gut microbiota. Gavage of wild-type mice with R. gnavus enhanced anti–PD-1–mediated tumor elimination, recapitulating the effect occurring in the absence of TREM2. A proinflammatory intestinal environment coincided with expansion, increased circulation, and migration of TNF-producing CD4 + T cells to the tumor bed. Thus, TREM2 remotely controls anti–PD-1 immune checkpoint blockade through modulation of the intestinal immune environment and microbiota, with R. gnavus emerging as a potential probiotic agent for increasing responsiveness to anti-PD-1.

30 March 2022 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
FKFabian Klein
Fabian Klein
JRJulien Roux
Julien Roux
GCGrozdan Cvijetic
Grozdan Cvijetic
PRPatrick Fernandes Rodrigues
Patrick Fernandes Rodrigues
LMLilly von Muenchow
Lilly von Muenchow
RTRoxane Tussiwand
Roxane Tussiwand

1 October 2020 in Molecular Immunology
Verified
Journal Article
Closed access
PRPatrick Fernandes Rodrigues
Patrick Fernandes Rodrigues
RTRoxane Tussiwand
Roxane Tussiwand

5 March 2026 in Science
Verified
Journal Article
Closed access
YCYun Chen
Yun Chen
YLYizhou Liu
Yizhou Liu
KNKhai Nguyen
Khai Nguyen
JWJunjie Wu
Junjie Wu
SSSihui Song
Sihui Song
MCMarco Colonna
Marco Colonna
Alzheimer’s disease (AD) is the leading cause of dementia and is characterized by progressive amyloid accumulation followed by tau-mediated neurodegeneration. Despite advances in anti-amyloid immunotherapies, important limitations remain, highlighting the need for new therapeutic strategies. Here, we introduce anti-amyloid chimeric antigen receptors expressed in astrocytes (CAR-A) and validate their function in vitro. We show that two CAR-A designs reduce amyloid and associated pathology after plaque formation and prevent early plaque deposition in vivo. Single-nucleus RNA sequencing shows that CAR-A treatment induces a distinct glial response to amyloid pathology involving coordinated activity of astrocytes and microglia. Each construct additionally elicits distinctive, receptor-specific effects in astrocytes or microglia. Together, these findings support the therapeutic potential of CAR-A as a disease-modifying strategy for AD.